Featured Post

Best places to buy Kaspersky Anti-Virus in 2020 - Android Central

Best places to buy Kaspersky Anti-Virus in 2020 - Android CentralBest places to buy Kaspersky Anti-Virus in 2020 - Android CentralAntivirus Software Market Pin-Point Analyses of Industry Competition Dynamics to Offer You a Competitive Edge - 3rd Watch NewsAntivirus Software Market Research with Covid-19 after Effects - Apsters NewsAntivirus Software Market Scope by Trends, Opportunities to Expand Significantly by 2026 - Jewish Life NewsBest places to buy Kaspersky Anti-Virus in 2020 - Android CentralPosted: 28 Apr 2020 12:00 AM PDTKaspersky Anti-Virus is one of the best computer protection programs around, and has been thoroughly tested by several third-party labs and in our own in-house tests, too. The best place to purchase a copy of Kaspersky Anti-Virus is from Kaspersky itself. However, you can often find deals through other vendors. The trick is finding a trustworthy one, so you don't accidentally purchase and download malware instead of a legitimate copy of Kaspersky. Here a…

Bill Gates Calls For National Tracking System For Coronavirus During Reddit AMA - Forbes

Bill Gates Calls For National Tracking System For Coronavirus During Reddit AMA - Forbes

Bill Gates Calls For National Tracking System For Coronavirus During Reddit AMA - Forbes

Posted: 18 Mar 2020 04:34 PM PDT

Topline: A week after stepping down from the boards of Microsoft and Berkshire Hathaway, Bill Gates, cofounder of Microsoft and the second-richest person in the world with a net worth $97.8 billion, took to reddit for an Ask Me Anything on the Covid-19 coronavirus pandemic, sharing his thoughts on how best to deal with the outbreak and its possible long-term effects on the world.

  • A TED Talk by Gates from 2015 recently emerged called "The Next Outbreak? We're Not Ready," given during the Ebola epidemic, but as the White House administration faces criticism for not reacting quick enough, Gates reiterated that, "We did know it would happen at some point, either with a flu or some other respiratory virus…There was almost no funding."
  • Following the eventual end of the pandemic, Gates hopes that countries can work together to better prepare for similar situations, including the "need to have the ability to scale up diagnostics, drugs and vaccines very rapidly...the technologies exist to do this well if the right investments are made"; the $100 million his and his wife Melinda's Gates Foundation donated to fight the coronavirus is focused on those three areas.
  • Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, this week said that mass production of a vaccine would likely not occur for another 12-18 months, and Gates concurred, saying that lots of manufacturing will need to be built to provide "billions of vaccines to protect the world" and that the first vaccines, which would "go to healthcare workers and critical workers...could happen before 18 months if everything goes well, but we and Fauci and others are being careful not to promise this when we are not sure."
  • A study released this week by Imperial College in the UK stated that even with mitigation, the U.S. could see around 1 million deaths from the coronavirus, but Gates cautioned that "the parameters used in that model were too negative," pointing to China as "the most critical data we have" and that its social distancing approach was "able to reduce the number of cases."
  • Responding to a question on the Netherlands' "controlled distribution" strategy, Gates countered saying "The only model that is known to work is a serious social distancing effort ('shut down')," estimating that "If a country does a good job with testing and 'shut down' then within 6-10 weeks they should see very few cases and be able to open back up"; however, he also admitted that "The U.S is still not organized on testing."
  • Gates called for a "national tracking system similar to South Korea, saying that "in Seattle, the [University of Washington] is providing thousands of tests per day but no one is connected to a national tracking system" and that "Whenever there is a positive test it should be seen to understand where the disease is and whether we need to strengthen the social distancing."
  • With social distancing and many of his other answers, though, he addressed the difficult schism between wealthy and developing nations, saying that "rich countries" that push for testing and practice social distancing should avoid high levels of infection within 2-3 months, though, "I worry about all the economic damage but even worse will be how this will affect the developing countries who cannot do the social distancing the same way as rich countries and whose hospital capacity is much lower."

Crucial Quote: Gates addressing a now deleted question: "My retiring from public boards was not related to the epidemic but it does reinforce my decision to focus on the work of the foundation including it's work to help with the epidemic."

Key Background: Gates, who is now focusing more on the Gates Foundation, was joined by the foundation's global health lead Dr. Trevor Mundel and his chief scientific adviser, Dr. Niranjan Bose.

According to Johns Hopkins University, there have been 214,894 confirmed cases of the coronavirus with 8,732 reported deaths. Along with the White House's recommendation to avoid groups of over 10 people, some cities and counties in the U.S., like the Bay Area in California, may soon order "shelter in place" measures to further curb the spread of the virus.

Full coverage and live updates on the Coronavirus

‘Complete scam’: Anti-virus ‘Shut Out’ necklaces sold across Hong Kong despite bans around Asia - Hong Kong Free Press

Posted: 13 Mar 2020 12:00 AM PDT

A Japanese "anti-viral" product that has been banned around Asia remains widely available in Hong Kong stores, despite dubious claims that they can protect against viruses. Retailers have defended selling them during the coronavirus pandemic, but the Customs and Excise Department has told HKFP they are looking into the devices.

Toamit's Virus Shut Out claims that it is "experimentally proven to effectively block airborne particles and bacteria, as well as various epidemic viruses… reducing the chance of being infected or infecting others." The manufacturers claim it is suitable for the sick, elderly, children, and people with low immunity.

A 7-Eleven store in Central. Photo: Tom Grundy/HKFP.

The product contains chlorine dioxide, but Dr Ariane Davison – a virologist and immunologist – told HKFP that the necklace is a "complete scam," adding that it "will do nothing to protect you by inactivating respiratory viruses."

"[T]he device is worn around your neck – nowhere near your nose and mouth which are the key portals for Covid infection. Should you bring the device closer to your face, the active ingredient, chlorine dioxide, would cause severe respiratory and eye irritations and skin burns, as it is highly corrosive," she said.

Davison said that chlorine dioxide is used to sterilise hard surfaces, and should not be used near the face: Furthermore, unlike the targets of anti-mosquito devices such as 'Parakito' which work to repel flying insects, viruses are inanimate, and do not 'migrate' or become attracted to the 'Virus Shut Out,' worn around the neck. "This device is useless in protecting against Covid-19."

Banned around Asia

The device has been banned by eBay and Facebook, and both Vietnamese and Thai authorities have confiscated them.

Vietnamese authorities have said the product has no scientific basis. However, it is still available in Hong Kong at Bonjour stores, SASA, at 7-Eleven convenience stores, on HKTV mall and from Watsons pharmacies, for under HK$100.

Watsons defended the product in a response to HKFP, saying it was being advertised accurately: "Please note that supplier has made an official announcement on its website on 10 March 2020 to advise retailers to refrain from copying or advertising as if the concerned Virus Shut Out product is effective against the new coronavirus so as not to mislead the consumers. For details, please refer to this link. We sell this product at stores and online and we never make any such claim as well."

A spokesperson for Bonjour said they were still learning about the situation: "[T]he company has not mentioned the product is used against coronavirus and has not received any notification from customs at this moment."

7-Eleven's operator Dairy Farm did not respond in time for publication.

The Customs and Excise Department told HKFP on Friday that it enforces the Consumer Goods Safety Ordinance and Trade Descriptions Ordinance, "which aims at protecting consumers by prohibiting false trade descriptions, false, misleading or incomplete information and misstatements in respect of goods provided in the course of trade."

"Hong Kong Customs is looking into the matter that you raised in [the] enquiry," the statement said.

Customs and Excise Department Headquarters in North Point. Photo: Wikimedia Commons.

Those who violate the Trade Descriptions Ordinance risk a maximum fine of HK$500,000 or imprisonment for five years.

Toamit did not respond to enquires.

First detected in Hubei, China, Covid-19 has infected more than 128,000 people globally, and more than 4,700 have died from the SARS-like disease.

Windows 10 update breaks Windows Defender protection - WindowsLatest

Posted: 22 Mar 2020 12:00 AM PDT

Update for Windows Defender broke the antivirus scans on Windows 10, with the antivirus protection software reporting error "Items Skipped During Scan". For many users, Windows Defender scans are failing after a couple of minutes, confirming that "scan was skipped" and no threats were discovered on the device.

It's not clear what items were skipped during the scan by Windows Defender and we also don't know if Microsoft's antivirus software is able to detect any threats on Windows 10.

It's possible that Windows Defender warnings are false and scans were performed successfully. In our testing, both manual and automatic scans are failing with the following error message:

Item skipped in scan, due to exclusion setting, or network scanning disabled by admin

Windows Defender scan skipped

Windows Defender version 4.18.2003 or newer apparently introduced this bug when Microsoft was trying to fix other issues. The problem is specific to Windows 10, as other Windows operating systems including Windows 7 and 8 are not affected by this glitch.

"I do get that message with a manual quick scan or with a full scan. It happens whether/not I turn off Cloud-delivered Protection or Controlled Folder Access. I didn't try the other settings. I've got no folder excluded," one user reported.

"It seems like something caused the notification settings with the latest update to get weird. I did a scan with malwarebytes after and found nothing. I did also do a sfc /scannow and it found a corrupt file which seems to be related to OneDrive but that seems unrelated," another poster noted in Reddit.

According to the error message, Windows Defender Antivirus scans are skipped due to an item's exclusion or network scanning settings. Since the exclusion doesn't appear to be the issue in user reports, it's likely to be associated with a particular defender update or other updates pushed by Microsoft and device manufacturer.

Microsoft has yet to document problems with Windows Defender, but it appears that the offline scan feature is working without any issues at the moment.

Scientists are racing to find the best drugs to treat COVID-19 - The Verge

Posted: 23 Mar 2020 06:33 AM PDT

Three months into the novel coronavirus pandemic, it's still unclear which drugs could combat the viral disease and which won't — despite public figures like President Donald Trump extolling the unproven promise of some medications. With public health on the line, the scientific community is searching for answers faster than ever.

When the novel coronavirus tore through China in January and February, researchers and doctors quickly launched dozens of clinical trials to test existing medications against COVID-19, the disease caused by the novel coronavirus. But the research done so far in China hasn't generated enough data for conclusive answers.

"We commend the researchers around the world who have come together to systemically evaluate experimental therapeutics," said Tedros Adhanom, director-general of the World Health Organization (WHO), in a press briefing. "Multiple small trials with different methodologies may not give us the clear, strong evidence we need about which treatments help to save lives."

In their fight for "clear, strong evidence," the WHO is launching a multicountry clinical trial to test four drug regimens as COIVD-19 therapies: an experimental antiviral drug called remdesivir, the antimalarial drug chloroquine (or the related hydroxychloroquine), a combination of two HIV drugs, and those same two HIV drugs along with the anti-inflammatory interferon beta.

The trial will be flexible and could add or drop additional treatment approaches or locations over time. In that way, it appears to be similar to the adaptive trial that the National Institute of Allergy and Infectious Diseases started in the US in February, which initially set out to test remdesivir but could expand to other drugs. The US is not currently involved in the WHO trial.

Hundreds of other clinical trials are underway, and other groups also continue to test the medications that the WHO selected — here's a breakdown of some of the drugs that researchers are zeroing in on.

Chloroquine and Hydroxychloroquine

Studies found that hydroxychloroquine and the related chloroquine can stop the novel coronavirus from infecting in cells in the lab, and anecdotal evidence suggests that it may help patients with COVID-19. Because the drug has been around for decades as an antimalarial treatment, scientists have experience with it.

"It's a known medicine," says Caleb Skipper, an infectious disease postdoctoral fellow at the University of Minnesota who's working on a smaller trial of the drug. "Little blips of lab data over the last several years show this drug has activity against viruses."

Skipper's trial is looking to see if hydroxychloroquine can prevent people who are exposed to the virus from developing severe disease. They're hoping to recruit health care workers, who are at a high risk of exposure to the virus, to participate in the trial.

The goal, Skipper says, is to get the drug in people's systems early. "Particularly with viruses, the earlier you inhibit their ability to replicate the better off you're going to be. If a drug is going to work, it is more likely to work early on in disease," he says. "If you catch someone really early and provide treatment early virus will have replicated a lot less."

The existing evidence on hydroxychloroquine points in the right direction, Skipper says, but all of the research on the drug is still in very early stages. "It's a long ways from being proven effective," he says.

Despite the limited evidence available, public figures, including Elon Musk and Trump, are pushing the message that hydroxychloroquine and chloroquine are the solutions to the outbreaks. "I feel good about it. That's all it is, just a feeling, you know, smart guy. I feel good about it," Trump said in a press conference on Friday.

As a result of the hype, demand for the drug has spiked, and manufacturers are increasing production. In Nigeria, two people overdosed on the medication after Trump said it could cure COVID-19. People who take it for other conditions, like lupus, are struggling to access their usual supply.

To be very clear, there is still no conclusive evidence that chloroquine will treat COVID-19. And treatments that appear promising based on anecdotal reports or "feelings" often don't end up working, which scientists know well: the majority of clinical trials fail, and they're seeing that reinforced in coronavirus treatment efforts.


In February, doctors in Thailand said they saw their COVID-19 patients improve on the combination of two HIV drugs, lopinavir–ritonavir. The WHO is testing the drug combination in their trial, along with anti-inflammatory interferon beta, which the body produces naturally to ward off viruses. The drug combination was used in patients during the SARS and MERS outbreaks, and it appeared to help.

But a clinical trial of those two drugs in China just found that patients with COVID-19 who were given the drugs did not improve more quickly than patients who didn't receive it.

The study, which was published this week, focused on a group of 199 severely ill patients, which may be why the drug wasn't effective — the patients were already too sick. But Timothy Sheahan, a coronavirus expert and assistant professor at the University of North Carolina Gillings School of Global Public Health, says he wasn't surprised the drug didn't work. "We've done work on that particular drug cocktail," he says. "The fact it failed is totally in step with everything we've done in the past."


The antiviral drug remdesivir was first developed to treat Ebola, but research later showed that it could also block MERS and SARS in cells. Lab tests have shown that it can inhibit the novel coronavirus in cells as well.

There's also anecdotal evidence that remdesivir helps treat COVID-19 patients, but that's also no guarantee that a clinical trial will show that it works better than a placebo. That's why the data collected on the drug through the WHO trial, the US adaptive trial, and the other studies is so important: before giving it to sick people en mass, doctors have to be sure that it actually works.

Other drugs

Though not a part of the WHO trial, Chinese officials also reported that the Japanese anti-flu drug favipiravir, which it tested in clinical trials, was effective in treating COVID-19 patients. Japan is studying the drug more closely, though data from those trials on the drug has not yet been published. Based on the drug's antiviral activity in cells, Sheahan says he'd be surprised if this drug ultimately ended up being effective. It doesn't work against MERS in cells, he says, and MERS is similar to the novel coronavirus.

In addition, some pharmaceutical companies are looking to repurpose anti-inflammatory drugs to try to calm lung inflammation in people with severe cases of COIVD-19; others are identifying the protective antibodies that people develop after they're infected with the virus in an effort to manufacture a treatment.

Clinical trials take time to collect data properly, so there likely won't be concrete evidence until next month or later. Patients are already receiving these drugs through compassionate use programs, which allows doctors to order experimental medications in certain cases, and under off-label use, where doctors prescribe drugs outside of what they're approved for. But ensuring the clinical trial process takes place alongside that, before jumping to conclusions about the best course of action, ensures patients can be treated based on evidence.

The sheer number of trials going on around the world for each particular treatment approach will give researchers more data to work with and data from different groups of people. "The more populations you can show a particular intervention works or does not work for, the more valuable that is," Skipper says. "The bigger amount of data available, the better."


Popular Posts

System detected an overrun of a stack-based buffer in this application [FIX] - Windows Report

Valorant anti-cheat lead answers many questions on Reddit - Millenium US